Preclinical Trial Equipment & Supplies In Ohio

AVROBIO has a preclinical research program for an investigational gene therapy for Gaucher disease type ...

Using the latest tools in bioengeneering, our researchers are now printing cancer tissues in 3D. These models can be used for highly significant pre-clinical trials and can be produced in 6/48/96 well plates for high throughput ...

AVROBIO has a preclinical research program for mucopolysaccharidosis type II (MPS II), or Hunter syndrome. The program is being developed in collaboration with Brian Bigger, Ph.D., who has published favorable preclinical data in a mouse model of Hunter ...

As with anti-PD-L1 therapies, PD-1 monotherapy and combinations have been associated with significant toxicities. Our preclinical studies have shown that CX-188 has the potential for an improved therapeutic index relative to PD-1 antibodies. The IND for CX-188 was cleared by the FDA. Following a program and portfolio prioritization, CytomX has decided to indefinitely postpone the ...

ES004 is a potentially best-in-class antibody targeting pan-allele signal-regulatory protein alpha (SIRPα). SIRPα is an inhibitory receptor expressed only on myeloid cells and dendritic cells. Binding of CD47 to SIRPα delivers a “don’t eat me” signal to suppress phagocytosis. Tumor cells frequently overexpress CD47 to evade macrophage-mediated destruction. To ...

Venadaparib (IDX-1197) is a potent PARP inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promote the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells. IDX-1197 is under clinical development targeting multiple solid tumors as a monotherapy (including maintenance) and for combination with other anti-cancer ...

Equipped with pre-set, clinically studied NMES parameters, the Corrective Therapy Device® delivers proven electrical stimulation to correct the source of the pain. Get started on the path to relief during our biggest sale ever with savings of $200 and enjoy a 60-day at-home ...

The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv used by traditional Chimeric Antigen Receptor (CAR) T cells. We believe this DAR has been demonstrated in preclinical studies greater specificity, stability and potency. ...

A new in silico tool for early screening of compounds multicurrent blocking effects on a population of hiPSC-derived ...

The RSOM Explorer P50 consists of a compact mobile cart system with a light-tight imaging chamber including a live-view camera for experiment supervision and a heated animal bed with integrated anesthesia supply. While raster-scanning the field of view, a nanosecond pulsed 532 nm laser excites the tissue. The induced ultrasound signal is detected by a broadband transducer with 50 MHz center ...

We designed ES005 to block LAG3 ligands, including MHC class II and FGL1. Through unique epitope binding, ES005 is able to recognize human LAG3 with high affinity. In preclinical studies, ES005 inhibited tumor growth both as a monotherapy and in combination with a PD-1 ...

Early-Stage Preclinical Program: 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways. BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against multiple RAS transformed tumors. ...

easyTEL is a fully implantable telemetry system, that transmits physiological data from conscious freely moving small subjects weighing 20 g or more, single-housed. Intended for use in preclinical research, easyTEL-S size implants are ideal for mice and offer the ability to continuously record Biopotential (ECG, EEG, EMG, EOG)* , Core Body Temperature and ...

Yso2 is a preclinical program targeting Crohn’s disease. It aims to develop Christensenella gut bacteria as a safe, efficient and groundbreaking oral biotherapy. YSOPIA has identified a lead candidate to relieve Crohn’s disease associated symptoms and slow down disease progression. ...

IVX-121 targets respiratory syncytial virus (RSV), a major cause of viral pneumonia for which no vaccine has been FDA approved. IVX-121 incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-Cav1; Science 2019). RSV F is known to undergo major structural changes that allow viral entry into the host cell, and during that process, critical protective epitopes are lost. Protein ...

Wolfmet 3D, developed by M&I Materials Ltd, leverages a sophisticated selective laser melting (SLM) technique for additive manufacturing. This process involves the use of a high-powered laser to meticulously fuse layers of pure tungsten powder. The result is the creation of highly intricate and precise components such as collimators and radiation shields used in medical imaging systems like ...

AM-125 for the treatment of vertigo is expected to complete its Phase 2 TRAVERS trial in Q2 2022 and to move into Phase 3 in Q4 2022. Keyzilen® (AM-101) for the treatment of acute inner ear tinnitus and Sonsuvi® (AM-111) for the treatment of acute inner ear hearing loss have both been evaluated in Phase 3 trials, but will require further clinical testing. ...

Plasmid DNA in reproducible and certified quality for preclinical and veterinary research. Cultivation without use of animal derived media. Controlled removal of bacterial LPS endotoxins. Complete removal of RNA and proteins. A large number of quality tests already inclusive – without any additional ...

TransIT-VirusGEN SELECT Transfection Reagent is designed to enhance delivery of packaging and transfer vector DNA to suspension and adherent HEK 293 cell types in order to increase production of recombinant lentivirus and adeno-associated virus (AAV). Key benefits of TransIT-VirusGEN SELECT Transfection Reagent include: Performance – Efficient DNA delivery for large-scale production of ...

We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled clinical trials evaluating both topical and intranasal routes of ...